Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2002



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Malaria's Challenge: From Infants to Genomics to Vaccines (J7)


Organizer(s) Stephen L. Hoffman and Carole A. Long
March 3—8, 2002
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 16, 2001
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 3, 2002


Summary of Meeting:
The malaria and human genome projects, and recent advances in epidemiology, immunology, and vaccinology provide unique opportunities for developing methods to control malaria, a disease that kills more children annually, and has influenced the human genome more than any other infectious disease. Despite a century of research, the 2 major drugs for severe malaria were introduced by ancient Chinese (artemesinin) and Amerindian (quinine) healers, and no subunit vaccine has ever been produced against a complex, multi-stage, variant parasite like P. falciparum. The goal of this meeting is for scientists to examine host-parasite interactions in model systems and in endemic areas that provide the foundation for malaria vaccine development; review recent results from clinical trials of malaria vaccines; and discuss how these data and that from the malaria and human genome projects, computational biology, quantitative epidemiology, molecular immunology; and new vaccine technologies are being used to develop vaccines to control this ancient scourge.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 3

16:00—19:00
Registration

Shavano Peak Foyer
18:15—19:15
Welcome

Shavano Peak Foyer
19:15—19:30
Orientation

Torreys Peak 1-2
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
David S. Roos, University of Pennsylvania, USA
Designing and Mining Parasite Genome Databases

19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
Jeff Sachs, Earth Institute at Columbia University, USA
The Economics of a Malaria Vaccine: Costs, Benefits and Incentives


MONDAY, MARCH 4

07:00—08:00
Breakfast

Red Cloud
08:00—11:00
Defining the Malaria Problem and the Human Models Indicating Developing Vaccines is Feasible
Meeting has ended...abstracts no longer viewable online.

Torreys Peak1-2
* Louis H. Miller, National Institutes of Health, USA

Kevin Marsh, University of Oxford, Kenya
Malaria Vaccination: What are We Trying to Prevent?

Stephen L. Hoffman, Sanaria, USA
Induction of Protection Against Malaria in Naïve Humans by Experimental Exposure to Whole Parasites

Andrew G. Clark, Cornell University, USA
The Role of Population Biology and Genetics in Developing Strategies for Malaria Vaccine Development

Andrew Read, Pennsylvania State University, USA
Imperfect Vaccines and the Evolution of Virulence

08:00—11:00
Impact of Parasite Genomics on Drug Target Selection. Sponsored by The Burroughs Wellcome Fund.
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Peter J. Myler, Seattle Biomedical Research Institute, USA
Kinetoplast Genome Projects

Daniel J. Carucci, Foundation for the National Institutes of Health, USA
Exploring the Malaria Genome for Targets of Vaccines and Drugs

Terry Gaasterland, University of California, San Diego, USA
Computational Analysis of the Trypanosoma brucei Genome

Stephen M. Beverley, Washington University School of Medicine, USA
Molecular Approaches to Trypanosomatid Pteridine Metabolic Pathways and Their Role(s) in Virulence and Chemotherapy

Sebastian Ulbert, Netherlands Cancer Institute, Netherlands
Short Talk: The Significance of Base J in the DNA of Trypanosoma brucei for the Base Excision Repair

Christian Doerig, Monash University, Australia
Short Talk: A Chemical Genetics Approach for Functional Studies and Target Validation of Plasmodium Protein Kinases

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Shavano Peak
13:00—22:00
Poster Viewing

Shavano Peak
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Genes, Genomics and Malaria. Session Sponsored by The Burroughs Wellcome Fund
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Victor Nussenzweig, New York University, USA

Louis H. Miller, National Institutes of Health, USA
Genes Involved in Susceptibility to Malaria

Ross L. Coppel, Monash University, Australia
How is the Malaria Genome Facilitating Studies on Malaria?

Mani Subramanian, Celera Genomics, USA
The Potential Impact of the Human Genome Project on Malaria and Other Infectious Diseases

17:00—19:00
Target Selection and Drug Development-I
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Daniel E. Goldberg, Washington University, USA
The Biochemistry of Hemoglobin Digestion in P. falciparum

Gary H. Posner, Johns Hopkins University, USA
Mechanism-Based Rational Design of New Antimalarial Peroxides

James H. McKerrow, University of California, San Diego, USA
Inhibitors of Thiol Proteases for Treating Chagas Disease

Akhil B. Vaidya, Drexel University College of Medicine, USA
Selective Interference with Parasite Mitochondrial Functions

19:00—20:00
Welcome Mixer

Shavano Peak
20:00—22:00
Poster Session 1: Defining the Malaria Problem and the Human Models Indicating Developing Vaccines is Feasible; Genes, Genomics, and Malaria

Shavano Peak

TUESDAY, MARCH 5

07:00—08:00
Breakfast

Red Cloud
08:00—11:00
Immunological Mechanisms of Protective Immunity
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Martha Sedegah†, Naval Medical Research Center, USA

Eleanor M. Riley, Roslin Institute, UK
Regulation of Innate and Adaptive Immunity to Malaria in Humans

Denise L. Doolan, James Cook University, Australia
Immunological Mechanisms of Protective Immunity Induced by Radiation Attenuated Sporozoites

Allan J. Saul, National Institutes Of Health, USA
Nature and Immunologic Mechanisms of Protective Immunity Against Mosquito Stage Parasites

Michael F. Good, Griffith University, Australia
Short Talk: Induction of Malaria Cell Mediated Immunity and Target Antigen Identification

08:00—11:00
Structure-Based Drug Design
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Gerhard Klebe, Philipps University Marburg, Germany
New Leads from De Novo Design and Virtual Screening for the Treatment of Shigellosis and Malaria

William T. Windsor, Schering-Plough Research Institute, USA
Structure Based Design of Protein Farnesyltransferase Inhibitors

William N. Hunter, University of Dundee, UK
X-ray Studies of Trypanothione Reductase; The Discovery of Novel Inhibitors

Timothy A.J. Haystead, Duke University, USA
Discovery of a New Antimilarial Target in the Human Purine Binding Proteome

Vern L. Schramm, Albert Einstein College of Medicine, USA
Short Talk: Inhibition of PNP by Immucillins Induces Purine-Less Death of Plasmodium falciparum in Cultured Erythrocytes

Meg Phillips, University of Texas Southwestern Medical Center, USA
Short Talk: Interactions in the Dimer Interface of Trypanosoma brucei Ornithine Decarboxylase: Implications for Drug Design

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Shavano Peak
13:00—22:00
Poster Viewing

Shavano Peak
14:30—16:30
Open Discussion: Are We Missing Something? Why is it Taking So Long to Develop Effective Malaria Vaccines?

Torreys Peak 1-2
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Identifying the Antigenic Targets (Proteins and Epitopes) of Protective Immune Responses. Session Sponsored by Science Applications International Corp. (SAIC)
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Robin Fredric Anders†, La Trobe University, Australia

Anthony A. Holder, Medical Research Council, UK
Antibodies to Merozoite Surface Proteins and Inhibition of Erythrocyte Invasion

Alessandro Sette, La Jolla Institute for Allergy & Immunology, USA
The Multi-Epitope Approach to Development of Malaria Vaccine

Daniel J. Carucci, Foundation for the National Institutes of Health, USA
Exploring the Malaria Genome for Targets of Vaccines and Drugs

Patrick E. Duffy, NIAID, National Institutes for Health, USA
Variant Surface Antigens on Infected Erythrocytes: Vaccine Prospects

17:00—19:00
Target Selection and Drug Development-II
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Richard R. Tidwell, University of North Carolina at Chapel Hill, USA
Pentamidine-Type Compounds as Antiprotozoan Agents. Contemporary Investigations of these Molecules.

Henri Vial, Universite Montpellier II, France
Peculiarities of the Phospholipid Metabolism in the Malaria-Causing Parasite Plasmodium and Pharmacological Implications

Philip J. Rosenthal, University of California, San Francisco, USA
Cysteine Protease Inhibitors to Treat Malaria

Frederick S. Buckner, University of Washington, USA
Sterol Biosynthesis and Protein Prenylation Pathways as Targets for Anti-Protozoan Chemotherapy

19:00—20:00
Welcome Mixer

Shavano Peak
20:00—22:00
Poster Session 2: Immunological Mechanisms of Protective Immunity; Identifying the Antigenic Targets (Proteins and Epitopes) of Protective Immune Responses

Shavano Peak

WEDNESDAY, MARCH 6

07:00—08:00
Breakfast

Red Cloud
08:00—11:00
Pre-Clinical Research and Development
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Rafi Ahmed, Emory University School of Medicine, USA
Vaccines and Immune Memory

08:00—11:00
Target Selection, Drug Resistance
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Paul A.M. Michels, Christian de Duve Institute of Cellular Pathology, Belgium
Glycosomes of Trypanosomes as Target for Drug Design

Aloysius G.M. Tielens, University of Utrecht, Netherlands
Mitochondrial Metabolism as Possible Drug Target?

Pradipsinh K. Rathod, University of Washington, USA
Initiation of Malaria Drug Resistance Through Hypermutations

Dyann F. Wirth, Harvard School of Public Health, USA
Molecular Genetics of Leishmania and Plasmodium: Implications for Drug Discovery and Drug Resistance

David C. Warhurst, London School of Hygiene and Tropical Medicine, UK
Short Talk: Understanding Drug-Resistance of Plasmodium falciparum DHFR by Homology Modeling

Jeanne A. Geyer, Walter Reed Army Institute of Research, USA
Short Talk: Drug Treatment and Genomic Stability in Plasmodium falciparum

08:30—09:30
Rountable: How Does One Optimize the Magnitude, Quality, and Longevity of T Cell Responses in Humans?
Meeting has ended...abstracts no longer viewable online.

* Stephen L. Hoffman, Sanaria, USA

* Adrian V. S. Hill, Jenner Institute, University of Oxford, UK

09:30—11:00
Pre-Clinical Research and Development
Meeting has ended...abstracts no longer viewable online.

Garnett H. Kelsoe, Duke University and Medical Center, USA
Infection, Inflammation and the Induction of Peripheral V(D)J Rearrangement

Speaker to be Announced
Applied Perspective: How Does One Optimize the Magnitude, Quality, and Duration of B Cell Responses?

09:20—09:40
Coffee Break

Shavano Peak Foyer
11:00—13:00
Poster Setup

Shavano Peak
13:00—22:00
Poster Viewing

Shavano Peak
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
Pre-Clinical Development and Clinical Testing
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Chetan E. Chitnis†, International Centre for Genetic Engineering and Biotechnology, India

Ruth S. Nussenzweig, New York University School of Medicine, USA
Special Lecture: From Rodents to Humans: 35 Years of Malaria Vaccine Development

Carole A. Long, National Institutes of Health, USA
Laboratory Correlates of in vivo Protective Responses

Pedro L. Alonso, World Health Organization, Switzerland
Field Trials of Malaria Vaccines

17:00—19:00
Target Selection and Drug Development-III
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Donald J. Krogstad, Tulane University Health Sciences Center, USA
Aminoquinoline Antimalarials Active Against Multiply-Resistant P. falciparum

Dennis M. Schmatz, Merck Research Laboratories, USA
The Drug Discovery Process: A Pharmaceutical Perspective

Buddy Ullman, Oregon Health & Science University, USA
Nucleoside Transporters of Protozoan Parasites

Wim G.J. Hol, University of Washington, USA
Medicinal Protein Crystallography and Structural Genomics for Tropical Diseases

19:00—19:45
Roundtable: Outcome Variables for Clinical Trials
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Pedro L. Alonso, World Health Organization, Switzerland

* Kwadwo Ansah Koram†, Noguchi Memorial Institute for Medical Research, Ghana

19:00—20:00
Welcome Mixer

Shavano Peak
20:30—22:30
Poster Session 3: Pre-Clinical Research and Development; Clinical Testing; Current Status of Efficacy Trials of Malaria Vaccines

Shavano Peak

THURSDAY, MARCH 7

07:00—08:00
Breakfast

Red Cloud
08:00—11:00
Current Status of Efficacy Trials of Malaria Vaccines. Session Sponsored by GlaxoSmithKline Biologicals S.A.
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Joe D. Cohen†, GlaxoSmithKline Biologicals, Belgium

D. Gray Heppner, Walter Reed Army Institute of Research, USA
Current Status of Clinical Trials with RTS, S and MSP-1 and AMA-1 Recombinant Protein Vaccines

Thomas L. Richie, Sanaria Inc., USA
Clinical Trials of Multi-Stage DNA Malaria Vaccines

Adrian V. S. Hill, Jenner Institute, University of Oxford, UK
Clinical Trials of Protective T Cell Inducing Vaccines

Speakers to be Announced
Short Updates from Other Speakers on Their Clinical Trials

08:00—11:00
Target Selection and Drug Development-IV
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Michael Riscoe, Oregon Health & Science University, USA
Exploitation of Parasite Heme Metabolism by Xanthones

Nicholas J. Westwood, University of St Andrews, UK
Chemical Genetic Approaches in Parasitology

Andrew D. Hamilton, Yale University, USA
Protein Farnesyltransferase as a Novel Target for the Design of Anti-Parasitic Agents

Sanjeev Krishna, St. George's Hospital Medical School, UK
The Plasmodium Falciparum Hexose Transporter is a Promising New Drug Target

Eric Oldfield, University of Illinois at Urbana-Champaign, USA
Short Talk: Prenyl Diphosphate Synthase Inhibitors as Anti-Parasitic Agents

Norman C. Waters, United States Military Academy, USA
Short Talk: Targeting the Plasmodial Cell Cycle Machinery Through Development of Novel Cyclin Dependent Protein Kinase Inhibitors

09:20—09:40
Coffee Break

Shavano Peak Foyer
16:30—17:00
Coffee & Snacks Available

Shavano Peak Foyer
17:00—19:00
From Research to Deployed Malaria Vaccine
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 1-2
* Robert Sauerwein†, Radboud University, Netherlands

Regina N. Rabinovich, ISGlobal, Spain / Harvard T.H. Chan School of Public Health, USA, Spain
Is Current Investment Adequate Enough to Develop a Potential Malaria Vaccine?

Speakers to be Announced
Discussion Group

16:00—18:00
Target Selection and Drug Development-V
Meeting has ended...abstracts no longer viewable online.

Torreys Peak 3-4
* Julio A. Urbina, Venezuelan Institute for Science Research, USA
Isoprenoid and Sterol Biosynthesis Enzymes as Chemotherapeutic Targets in Trypanosomatid Parasites: Chemical Validation

Glaucius Oliva, University of São Paulo, Brazil
Rational Design and Biodiversity in the Search of New Anti-Chagasic Drugs

Ching-Chung Wang, University of California, San Francisco, USA
The Presence of an Essential Ubiquitin-Proteasome Pathway in Trypanosoma brucei

Jeremy C. Mottram, University of Glasgow, UK
Unusual Cysteine Proteases as Drug Targets in Trypanosomatids

18:00—19:00
Plenary
Meeting has ended...abstracts no longer viewable online.

Simon L. Croft, London School of Hygiene & Tropical Medicine, UK
Short Talk: Miltefosine for the Treatment of Leishmaniasis

Solomon O. Nwaka, World Health Organization, Switzerland
Short Talk: Medicines for Malaria Venture: New Paradigm for the Discovery and Development of Antimalarial Drugs

Victoria G. Hale, Institute for OneWorld Health, USA
Short Talk: The Institute for One World Health: Filling the Gaps in the Development of New Drugs for Neglected Diseases

19:00—20:00
Welcome Mixer

Shavano Peak
20:00—23:00
Entertainment

Shavano Peak

FRIDAY, MARCH 8

 
Departure


*Session Chair †Invited, not yet responded.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676